Lupin Cuts Forecast Despite Etanercept Launch

Firm Sees Trump 'Buy American' Order As Near-Term Opportunity

Despite plans to launch a biosimilar to Enbrel in August and a generic to ProAir in September, Lupin cut its FY21 EBITDA forecast to 17% from 19-20%, as first-quarter revenues were hit by COVID-19 and a recall of metformin in the US. Meanwhile, it sees the US “Buy American” order for some essential medicines as a near-term opportunity.

Earnings Season Company Reports Stock Market Ticker Words 3d Illustration
Lupin's First Quarter Performance Guides Lower FY21 Forecast • Source: Shutterstock

Lupin is hopeful of a revival in US sales from the third quarter at most but has cut its FY2021 EBITDA estimate to 17% from 19-20% guided earlier.

The revision was made after sales of flu products halved, metformin was recalled and demand contracted due to advance stocking...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business